GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one ...
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...
Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...
GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback